-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
the	O
use	O
of	O
oxytocin	B-I
on	O
blood	O
loss	O
during	O
different	O
postpartum	O
periods	O
.	O

METHODS	O
:	O
In	O
the	O
study	O
,	O
89	O
pregnant	O
women	O
to	O
whom	O
oxytocin	B-I
was	O
administered	O
after	O
placenta	O
separation	O
were	O
studied	O
in	O
Group	O
1	O
,	O
89	O
pregnant	O
women	O
were	O
included	O
in	O
Group	O
2	O
,	O
and	O
oxytocin	B-I
was	O
administered	O
after	O
delivery	O
of	O
the	O
shoulder	O
.	O

The	B-O
levels	I-O
of	I-O
hemoglobin	I-O
and	O
hematocrit	B-O
before	O
and	O
after	O
delivery	O
were	O
quantified	O
.	O

-DOCSTART-	O

Title	O
:	O
Chocolate	B-I
frogs	I-I
do	O
not	O
increase	O
completion	O
of	O
parent	O
survey	O
:	O
randomised	O
study	O
.	O

METHODS	O
:	O
Families	B-P
enrolled	I-P
between	I-P
15	I-P
March	I-P
and	I-P
25	I-P
May	I-P
2012	I-P
were	O
randomised	O
to	O
receive	O
a	B-I
chocolate	I-I
frog	I-I
versus	O
no	B-C
chocolate	I-C
frog	I-C
.	O

Both	O
groups	O
received	O
a	O
written	O
reminder	O
and	O
replacement	O
survey	O
2	O
weeks	O
after	O
the	O
survey	O
was	O
posted	O
and	O
up	O
to	O
two	O
telephone	O
reminders	O
thereafter	O
.	O

We	O
analysed	O
the	O
effect	O
of	O
the	O
incentive	O
using	O
?	O
(	O
2	O
)	O
tests	O
for	O
the	B-O
categorical	I-O
response	I-O
variable	O
and	O
t	O
-	O
tests	O
for	O
the	B-O
continuous	I-O
reminder	I-O
and	O
length	B-O
of	I-O
response	I-O
variables	I-O
at	O
the	O
end	O
of	O
(	O
i	O
)	O
randomisation	O
and	O
(	O
ii	O
)	O
the	O
study	O
(	O
1	O
November	O
2012	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
phase	O
II	O
study	O
of	O
afatinib	B-I
versus	O
cetuximab	B-I
in	O
metastatic	O
or	O
recurrent	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

METHODS	O
:	O
An	O
open	O
-	O
label	O
,	O
randomized	O
,	O
phase	O
II	O
trial	O
was	O
conducted	O
in	O
43	O
centers	O
;	O
124	B-P
patients	I-P
were	O
randomized	O
(	O
1	O
:	O
1	O
)	O
to	O
either	O
afatinib	B-I
(	O
50	O
mg	O
/	O
day	O
)	O
or	O
cetuximab	B-I
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
)	O
until	O
disease	O
progression	O
or	O
intolerable	O
adverse	O
events	O
(	O
AEs	O
)	O
(	O
stage	O
I	O
)	O
,	O
with	O
optional	O
crossover	O
(	O
stage	O
II	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
tumor	B-O
shrinkage	I-O
before	O
crossover	O
assessed	O
by	O
investigator	O
(	O
IR	O
)	O
and	O
independent	O
central	O
review	O
(	O
ICR	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Electrothermal	B-I
arthroscopic	I-I
capsulorrhaphy	I-I
:	O
old	O
technology	O
,	O
new	O
evidence	O
.	O

A	O
multicenter	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Patients	B-P
(	I-P
>	I-P
14	I-P
years	I-P
)	I-P
diagnosed	I-P
with	I-P
multidirectional	I-P
instability	I-P
or	I-P
multidirectional	I-P
laxity	I-P
with	I-P
anteroinferior	I-P
instability	I-P
and	I-P
failed	I-P
nonoperative	I-P
treatment	I-P
were	O
enrolled	O
.	O

Patients	O
with	O
bone	O
lesions	O
or	O
labral	O
,	O
biceps	O
anchor	O
,	O
or	O
full	O
-	O
thickness	O
rotator	O
cuff	O
tears	O
were	O
excluded	O
intraoperatively	O
.	O

Outcomes	O
included	O
Western	B-O
Ontario	I-O
Shoulder	I-O
Instability	I-O
Index	I-O
,	O
function	B-O
and	O
recurrent	B-O
instability	I-O
at	O
2	O
years	O
postoperatively	O
,	O
and	O
surgical	B-O
times	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Compared	O
with	O
the	O
intake	O
of	O
commercial	B-C
vegetable	I-C
juice	I-C
,	O
the	O
intake	O
of	O
fresh	B-I
fruit	I-I
and	O
komatsuna	B-I
(	I-I
Brassica	I-I
rapa	I-I
L	I-I
.	I-I
var	I-I
.	I-I
perviridis	I-I
)	I-I
juice	I-I
mixture	I-I
reduces	O
serum	O
cholesterol	O
in	O
middle	B-P
-	I-P
aged	I-P
men	I-P
:	O
a	O
randomized	O
controlled	O
pilot	O
study	O
.	O

METHODS	O
:	O
This	O
study	O
was	O
performed	O
as	O
a	O
single	O
blind	O
and	O
randomized	O
controlled	O
trial	O
.	O

Subjects	B-P
were	I-P
16	I-P
men	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
46	I-P
.	I-P
4	I-P
	I-P
7	I-P
.	I-P
1	I-P
years	I-P
)	I-P
,	O
and	O
they	O
were	O
divided	O
into	O
two	O
groups	O
(	O
control	O
group	O
and	O
intervention	O
group	O
)	O
.	O

The	O
intervention	O
group	O
consumed	O
the	B-I
juice	I-I
mixture	I-I
of	I-I
fresh	I-I
fruit	I-I
and	O
B	B-I
.	I-I
rapa	I-I
.	O

The	O
control	O
group	O
consumed	O
commercial	B-C
vegetable	I-C
juice	I-C
.	O

Subjects	O
consumed	O
juice	O
twice	O
a	O
day	O
throughout	O
the	O
weekday	O
,	O
for	O
4	O
weeks	O
.	O

We	O
prepared	O
both	O
juices	O
with	O
an	O
equivalent	O
energy	O
balance	O
.	O

-DOCSTART-	O

Title	O
:	O
Vitamin	B-I
D	I-I
supplementation	I-I
ameliorates	O
hypoinsulinemia	O
and	O
hyperglycemia	O
in	O
static	B-P
magnetic	I-P
field	I-P
-	I-P
exposed	I-P
rat	I-P
.	O

-DOCSTART-	O

Title	O
:	O
A	O
further	O
investigation	O
of	O
goal	O
-	O
directed	O
intention	O
understanding	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Transcervical	B-I
Foley	I-I
'	I-I
s	I-I
catheter	I-I
versus	O
Cook	B-I
balloon	I-I
for	O
cervical	O
ripening	O
in	O
stillbirth	O
with	O
a	O
scarred	O
uterus	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
study	O
.	O

El	O
Minia	O
University	O
Hospital	O
,	O
El	O
Minia	O
,	O
Egypt	O
.	O

Two	B-P
-	I-P
hundred	I-P
pregnant	I-P
women	I-P
with	I-P
stillbirth	I-P
,	I-P
unfavorable	I-P
cervix	I-P
and	I-P
scarred	I-P
uterus	I-P
were	O
recruited	O
into	O
this	O
study	O
.	O

They	O
were	O
randomized	O
into	O
two	O
groups	O
.	O

In	O
group	O
I	O
(	O
n	O
=	O
100	O
)	O
,	O
cervical	B-I
ripening	I-I
was	O
done	O
using	O
Foley	B-I
'	I-I
s	I-I
catheter	I-I
.	O

In	O
group	O
II	O
(	O
n	O
=	O
100	O
)	O
,	O
cervical	B-I
ripening	I-I
was	O
done	O
using	O
Cook	B-I
cervical	I-I
ripening	I-I
balloon	I-I
.	O

Balloon	B-O
insertion	I-O
to	I-O
delivery	I-O
interval	I-O
,	O
successful	B-O
ripening	I-O
rate	I-O
,	O
cesarean	B-O
delivery	I-O
rate	I-O
,	O
maternal	B-O
adverse	I-O
events	I-O
and	O
maternal	B-O
satisfaction	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Coping	O
strategies	O
as	O
mediators	O
of	O
the	O
effect	O
of	O
the	B-I
START	I-I
(	I-I
strategies	I-I
for	I-I
RelaTives	I-I
)	I-I
intervention	I-I
on	O
psychological	O
morbidity	O
for	O
family	B-P
carers	I-P
of	I-P
people	I-P
with	I-P
dementia	I-P
in	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
260	B-P
family	I-P
carers	I-P
from	I-P
NHS	I-P
dementia	I-P
services	I-P
were	O
randomised	O
to	O
START	B-I
(	I-I
manualised	I-I
coping	I-I
skills	I-I
intervention	I-I
)	I-I
,	O
or	O
treatment	B-C
-	I-C
as	I-C
-	I-C
usual	I-C
(	I-C
TAU	I-C
)	I-C
.	O

Blinded	O
raters	O
administered	O
the	B-O
Hospital	I-O
Anxiety	I-O
and	I-O
Depression	I-O
Scale	I-O
(	I-O
HADS	I-O
-	I-O
T	I-O
)	I-O
and	O
Brief	B-O
COPE	I-O
inventory	O
at	O
baseline	O
,	O
4	O
and	O
8	O
months	O
.	O

HADS	B-O
-	I-O
T	I-O
improved	O
in	O
the	O
intervention	O
group	O
when	O
compared	O
to	O
TAU	B-C
at	O
all	O
levels	O
of	O
psychological	O
distress	O
.	O

We	O
tested	O
whether	O
coping	O
was	O
a	O
mediator	O
and	O
for	O
moderated	O
mediation	O
,	O
and	O
(	O
post	O
-	O
hoc	O
)	O
subgroup	O
treatment	O
effects	O
on	O
coping	O
.	O

-DOCSTART-	O

Title	O
:	O
Assessing	O
the	O
benefit	O
of	O
a	B-I
personalized	I-I
EHR	I-I
-	I-I
generated	I-I
informed	I-I
consent	I-I
in	O
a	O
dental	O
school	O
setting	O
.	O

METHODS	O
:	O
In	O
the	O
study	O
,	O
a	B-I
set	I-I
of	I-I
informed	I-I
consents	I-I
,	O
or	O
SmartConsents	B-I
,	O
were	O
developed	O
for	O
specific	O
diagnoses	O
and	O
procedures	O
,	O
enhanced	O
with	O
graphics	O
,	O
and	O
delivered	O
through	O
the	O
school	O
'	O
s	O
EHR	O
.	O

Fifty	B-P
patients	I-P
were	I-P
recruited	I-P
in	I-P
the	I-P
school	I-P
'	I-P
s	I-P
Urgent	I-P
Care	I-P
Clinic	I-P
and	O
divided	O
evenly	O
into	O
two	O
groups	O
:	O
one	O
(	O
control	O
)	O
receiving	O
the	B-C
standard	I-C
consent	I-C
,	O
with	O
the	O
second	O
receiving	O
a	B-I
SmartConsent	I-I
.	O

Following	O
treatment	O
,	O
patients	O
were	O
assessed	O
based	O
on	O
demographics	B-O
,	O
decisional	B-O
conflict	I-O
,	O
satisfaction	B-O
,	O
health	B-O
literacy	I-O
,	O
and	O
knowledge	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
effectiveness	O
of	O
bevacizumab	B-I
-	O
containing	O
treatment	O
for	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
:	O
final	O
results	O
of	O
the	O
ARIES	O
observational	O
cohort	O
study	O
.	O

METHODS	O
:	O
From	B-P
2006	I-P
to	I-P
2009	I-P
,	I-P
ARIES	I-P
enrolled	I-P
patients	I-P
with	I-P
locally	I-P
advanced	I-P
or	I-P
metastatic	I-P
NSCLC	I-P
who	O
were	O
eligible	O
for	O
bevacizumab	B-I
,	O
excluding	O
those	O
with	O
predominantly	O
squamous	O
histology	O
.	O

Patients	O
were	O
required	O
to	O
provide	O
informed	O
consent	O
and	O
to	O
have	O
initiated	O
bevacizumab	B-I
with	O
chemotherapy	B-I
within	O
4	O
months	O
before	O
enrollment	O
.	O

There	O
were	O
no	O
protocol	O
-	O
defined	O
treatments	O
or	O
assessments	O
.	O

The	O
dosing	O
of	O
bevacizumab	B-I
and	O
chemotherapy	B-I
,	O
and	O
the	O
choice	O
of	O
chemotherapy	O
regimen	O
,	O
was	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
.	O

-DOCSTART-	O

Title	O
:	O
GPs	B-I
'	I-I
experiences	I-I
with	I-I
brief	I-I
intervention	I-I
for	O
medication	O
-	O
overuse	O
headache	O
:	O
a	O
qualitative	O
study	O
in	O
general	O
practice	O
.	O

METHODS	O
:	O
Qualitative	O
study	O
in	O
Norwegian	O
general	O
practice	O
.	O

Data	O
were	O
collected	O
through	O
four	O
focus	O
group	O
interviews	O
with	O
22	B-P
GPs	I-P
who	O
participated	O
in	O
an	O
intervention	O
study	O
on	O
BI	O
for	O
MOH	O
.	O

Systematic	B-O
text	I-O
condensation	I-O
was	O
used	O
to	O
analyse	O
transcripts	O
from	O
the	O
focus	O
group	O
interviews	O
.	O

-DOCSTART-	O

Title	O
:	O
Gene	B-I
variants	I-I
in	I-I
CYP2C19	I-I
are	O
associated	O
with	O
altered	O
in	O
vivo	O
bupropion	O
pharmacokinetics	O
but	O
not	O
bupropion	O
-	O
assisted	O
smoking	O
cessation	O
outcomes	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
rhubarb	B-I
combined	O
with	O
early	B-I
enteral	I-I
nutrition	I-I
for	O
the	O
treatment	O
of	O
severe	O
acute	O
pancreatitis	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
126	I-P
patients	I-P
with	I-P
SAP	I-P
were	O
randomly	O
assigned	O
into	O
three	O
groups	O
:	O
parenteral	B-I
nutrition	I-I
group	O
,	O
treated	O
with	O
standard	O
solution	O
first	O
and	O
EN	B-I
14	O
days	O
later	O
;	O
EEN	B-I
group	O
,	O
treated	O
with	O
EN	B-I
suspension	I-I
;	O
or	O
EEN	B-I
combined	O
with	O
rhubarb	B-I
group	I-I
,	O
treated	O
with	O
rhubarb	B-I
and	O
then	O
EN	B-I
2	O
h	O
later	O
.	O

The	B-O
gastrointestinal	I-O
function	I-O
,	O
APACHE	B-O
II	I-O
scores	I-O
,	O
the	B-O
levels	I-O
of	I-O
plasma	I-O
IL	I-O
-	I-O
6	I-O
,	O
IL	B-O
-	I-O
11	I-O
,	O
C	B-O
-	I-O
reactive	I-O
proteins	I-O
(	I-O
CRP	I-O
)	I-O
and	O
the	B-O
liver	I-O
and	O
kidney	B-O
functional	I-O
measures	I-O
were	O
longitudinally	O
analyzed	O
.	O

-DOCSTART-	O

Title	O
:	O
Everolimus	B-I
for	O
subependymal	O
giant	O
cell	O
astrocytoma	O
in	O
patients	B-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
:	O
2	O
-	O
year	O
open	O
-	O
label	O
extension	O
of	O
the	O
randomised	O
EXIST	O
-	O
1	O
study	O
.	O

METHODS	O
:	O
We	O
assessed	O
data	O
from	O
a	O
prospective	O
,	O
open	O
-	O
label	O
extension	O
of	O
a	O
multicentre	O
,	O
phase	O
3	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
in	O
patients	B-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
who	I-P
had	I-P
SEGA	I-P
that	O
was	O
growing	O
and	O
needed	O
treatment	O
.	O

In	O
this	O
extension	O
study	O
,	O
we	O
included	O
all	O
patients	O
who	O
had	O
been	O
assigned	O
everolimus	B-I
during	O
the	O
double	O
-	O
blind	O
,	O
randomised	O
phase	O
of	O
the	O
trial	O
and	O
those	O
patients	O
who	O
crossed	O
over	O
from	O
the	B-C
placebo	I-C
group	O
to	O
receive	O
everolimus	B-I
during	O
the	O
randomised	O
phase	O
or	O
at	O
the	O
start	O
of	O
the	O
extension	O
phase	O
.	O

All	O
patients	O
received	O
oral	B-I
everolimus	I-I
at	O
a	O
starting	O
dose	O
of	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
.	O

Everolimus	B-I
dose	O
was	O
subsequently	O
adjusted	O
subject	O
to	O
tolerability	O
to	O
attain	O
blood	O
trough	O
concentrations	O
of	O
5	O
-	O
15	O
ng	O
/	O
mL	O
.	O

An	O
independent	O
central	O
radiology	O
review	O
team	O
assessed	O
SEGA	B-O
response	I-O
(	O
at	O
least	O
a	O
50	O
%	O
reduction	O
from	O
baseline	O
in	O
total	O
volume	O
of	O
all	O
target	O
SEGAs	O
;	O
the	O
primary	O
endpoint	O
)	O
by	O
MRI	B-O
at	O
12	O
,	O
24	O
,	O
and	O
48	O
weeks	O
,	O
then	O
every	O
year	O
thereafter	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	B-I
dose	I-I
of	I-I
everolimus	I-I
.	O

This	O
study	O
was	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT00789828	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
low	B-I
versus	O
high	B-I
dialysate	I-I
sodium	I-I
concentration	I-I
on	O
blood	O
pressure	O
and	O
endothelial	O
-	O
derived	O
vasoregulators	O
during	O
hemodialysis	O
:	O
a	O
randomized	O
crossover	O
study	O
.	O

METHODS	O
:	O
3	O
-	O
week	O
,	O
2	O
-	O
arm	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O

16	B-P
patients	I-P
with	I-P
intradialytic	I-P
hypertension	I-P
.	O

Low	B-I
(	I-I
5	I-I
mEq	I-I
/	I-I
L	I-I
below	I-I
serum	I-I
sodium	I-I
)	I-I
versus	O
high	B-I
(	I-I
5	I-I
mEq	I-I
/	I-I
L	I-I
above	I-I
serum	I-I
sodium	I-I
)	I-I
dialysate	I-I
sodium	I-I
concentration	I-I
.	O

METHODS	O
:	O
Mixed	O
linear	O
regression	O
was	O
used	O
to	O
compare	O
the	O
effect	O
of	O
dialysate	O
sodium	O
(	O
low	O
vs	O
high	O
)	O
and	O
randomization	O
arm	O
(	O
low	O
-	O
then	O
-	O
high	O
vs	O
high	O
-	O
then	O
-	O
low	O
)	O
on	O
intradialytic	O
changes	O
in	O
endothelin	B-O
1	I-O
,	O
NO2	B-O
(	I-O
-	I-O
)	I-O
,	O
and	O
BP	B-O
values	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Crohn	B-I
'	I-I
s	I-I
disease	I-I
management	I-I
after	O
intestinal	O
resection	O
:	O
a	O
randomised	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
trial	O
,	O
consecutive	B-P
patients	I-P
from	I-P
17	I-P
centres	I-P
in	I-P
Australia	I-P
and	I-P
New	I-P
Zealand	I-P
undergoing	I-P
intestinal	I-P
resection	I-P
of	I-P
all	I-P
macroscopic	I-P
Crohn	I-P
'	I-P
s	I-P
disease	I-P
,	I-P
with	I-P
an	I-P
endoscopically	I-P
accessible	I-P
anastomosis	I-P
,	I-P
received	I-P
3	I-P
months	I-P
of	I-P
metronidazole	I-P
therapy	I-P
.	O

Patients	O
at	O
high	O
risk	O
of	O
recurrence	O
also	O
received	O
a	B-I
thiopurine	I-I
,	O
or	O
adalimumab	B-I
if	O
they	O
were	O
intolerant	O
to	O
thiopurines	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
parallel	O
groups	O
:	O
colonoscopy	B-I
at	I-I
6	I-I
months	I-I
(	O
active	O
care	O
)	O
or	O
no	B-C
colonoscopy	I-C
(	O
standard	O
care	O
)	O
.	O

We	O
used	O
computer	O
-	O
generated	O
block	O
randomisation	O
to	O
allocate	O
patients	O
in	O
each	O
centre	O
to	O
active	O
or	O
standard	O
care	O
in	O
a	O
2	O
:	O
1	O
ratio	O
.	O

For	O
endoscopic	O
recurrence	O
(	O
Rutgeerts	O
score	O
?i2	O
)	O
at	O
6	O
months	O
,	O
patients	O
stepped	O
-	O
up	O
to	O
thiopurine	B-I
,	O
fortnightly	B-I
adalimumab	I-I
with	O
thiopurine	B-I
,	O
or	O
weekly	B-I
adalimumab	I-I
.	O

The	O
primary	O
endpoint	O
was	O
endoscopic	B-O
recurrence	I-O
at	O
18	O
months	O
.	O

Patients	O
and	O
treating	O
physicians	O
were	O
aware	O
of	O
the	O
patient	O
'	O
s	O
study	O
group	O
and	O
treatment	O
,	O
but	O
central	B-O
reading	I-O
of	I-O
the	I-O
endoscopic	I-O
findings	I-O
was	O
undertaken	O
blind	O
to	O
the	O
study	O
group	O
and	O
treatment	O
.	O

Analysis	O
included	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT00989560	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
functional	O
outcomes	O
and	O
predictors	O
of	O
shunt	B-I
-	I-I
dependent	I-I
hydrocephalus	O
after	O
treatment	O
of	O
ruptured	O
intracranial	O
aneurysms	O
in	O
the	O
BRAT	O
trial	O
:	O
revisiting	B-I
the	I-I
clip	I-I
vs	O
coil	B-I
debate	I-I
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
471	I-P
patients	I-P
who	O
were	O
part	O
of	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
from	O
2003	O
to	O
2007	O
were	O
retrospectively	O
reviewed	O
.	O

All	O
variables	O
including	O
demographic	B-O
data	I-O
,	O
medical	B-O
history	I-O
,	O
treatment	B-O
,	O
imaging	B-O
,	O
and	O
functional	B-O
outcomes	O
were	O
included	O
as	O
part	O
of	O
the	O
trial	O
.	O

No	O
additional	O
variables	O
were	O
retrospectively	O
collected	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Effects	O
of	O
Naltrexone	B-I
on	O
Subjective	O
Response	O
to	O
Methamphetamine	O
in	O
a	O
Clinical	O
Sample	O
:	O
a	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
Laboratory	O
Study	O
.	O

METHODS	O
:	O
Non	B-P
-	I-P
treatment	I-P
-	I-P
seeking	I-P
individuals	I-P
meeting	I-P
DSM	I-P
-	I-P
IV	I-P
criteria	I-P
for	I-P
MA	I-P
abuse	I-P
or	I-P
dependence	I-P
(	I-P
n=30	I-P
)	I-P
completed	O
two	O
separate	O
5	O
-	O
day	O
inpatient	O
stays	O
.	O

During	O
each	O
admission	O
,	O
participants	O
completed	O
testing	O
sessions	O
comprised	O
of	O
MA	B-O
cue	I-O
-	I-O
reactivity	I-O
and	O
intravenous	B-O
MA	I-O
administration	I-O
(	I-O
30	I-O
mg	I-O
)	I-O
after	O
receiving	O
oral	B-I
NTX	I-I
(	O
50	O
mg	O
)	O
or	O
placebo	B-C
for	O
4	O
days	O
.	O

This	O
study	O
tested	O
the	O
hypotheses	O
that	O
NTX	B-I
would	O
(	O
a	O
)	O
attenuate	O
cue	B-O
-	I-O
induced	I-O
MA	I-O
craving	I-O
,	O
and	O
(	O
b	O
)	O
reduce	O
subjective	B-O
responses	I-O
to	I-O
MA	I-O
administration	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Visual	O
Assessment	O
of	O
Relative	O
Apical	O
Sparing	O
Pattern	O
Is	O
More	O
Useful	O
Than	O
Quantitative	O
Assessment	O
for	O
Diagnosing	O
Cardiac	O
Amyloidosis	O
in	O
Borderline	O
or	O
Mildly	O
Increased	O
Left	O
Ventricular	O
Wall	O
Thickness	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
Quest	I-I
to	I-I
Lava	I-I
Mountain	I-I
Computer	I-I
Game	I-I
on	O
Dietary	O
and	O
Physical	O
Activity	O
Behaviors	O
of	O
Elementary	B-P
School	I-P
Children	I-P
:	O
A	O
Pilot	O
Group	O
-	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Quasi	O
-	O
experimental	O
group	O
-	O
randomized	O
controlled	O
trial	O
conducted	O
during	O
the	O
2012	O
-	O
2013	O
school	O
year	O
.	O

A	O
total	O
of	O
107	O
children	O
in	O
fourth	O
and	O
fifth	O
grade	O
consented	O
.	O

There	O
was	O
an	O
attrition	O
rate	O
of	O
8	O
.	O
8	O
%	O
with	O
a	O
final	O
sample	O
size	O
of	O
44	O
children	O
in	O
three	O
intervention	O
schools	O
,	O
and	O
a	O
sample	O
of	O
50	O
children	O
in	O
three	O
comparison	O
schools	O
.	O

Dietary	O
intake	O
was	O
measured	O
using	O
two	O
random	O
24	O
-	O
hour	O
recalls	O
,	O
whereas	O
child	B-O
self	I-O
-	I-O
report	I-O
surveys	I-O
measured	O
diet	B-O
,	O
physical	B-O
activity	I-O
,	O
and	O
psychosocial	B-O
factors	I-O
before	O
and	O
after	O
the	O
intervention	O
.	O

Process	O
data	O
on	O
QTLM	B-O
usability	I-O
and	O
back	B-O
-	I-O
end	I-O
server	I-O
data	I-O
on	I-O
QTLM	I-O
exposure	O
and	O
progress	O
achieved	O
were	O
collected	O
.	O

QTLM	B-I
was	O
implemented	O
as	O
part	O
of	O
the	O
in	O
-	O
school	O
or	O
afterschool	O
program	O
.	O

Recommended	O
game	O
exposure	O
duration	O
was	O
90	O
min	O
/	O
wk	O
for	O
6	O
weeks	O
.	O

Analysis	O
of	O
covariance	O
or	O
logistic	O
regression	O
models	O
evaluated	O
effects	O
of	O
QTLM	B-I
on	O
diet	B-O
,	O
physical	B-O
activity	I-O
,	O
and	O
psychosocial	B-O
factors	I-O
.	O

Post	O
hoc	O
exploratory	O
analysis	O
examined	O
the	O
changes	O
before	O
and	O
after	O
the	O
intervention	O
in	O
outcome	O
variables	O
among	O
children	O
in	O
the	O
intervention	O
group	O
.	O

Significance	O
was	O
set	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Comparison	O
of	O
Teaching	O
Modalities	O
and	O
Fidelity	O
of	O
Simulation	O
Levels	O
in	O
Teaching	O
Resuscitation	O
Scenarios	O
.	O

METHODS	O
:	O
Totally	B-P
39	I-P
medical	I-P
students	I-P
and	I-P
physician	I-P
assistant	I-P
students	I-P
were	O
randomly	O
assigned	O
to	O
4	O
training	O
conditions	O
:	O
control	O
(	O
lecture	B-C
only	O
)	O
,	O
video	B-I
-	I-I
based	I-I
didactic	I-I
instruction	I-I
,	O
low	B-I
-	I-I
,	O
and	O
high	B-I
-	I-I
fidelity	I-I
simulation	I-I
activities	I-I
.	O

Participants	O
were	O
assessed	O
using	O
a	O
baseline	O
written	B-O
pretest	I-O
of	I-O
ACLS	I-O
knowledge	I-O
.	O

Following	O
this	O
,	O
all	O
participants	O
received	O
a	B-I
lecture	I-I
outlining	O
ACLS	O
science	O
and	O
algorithm	O
interpretation	O
.	O

Participants	O
were	O
then	O
trained	O
in	O
specific	O
aspects	O
of	O
ACLS	O
according	O
to	O
their	O
assigned	O
instructional	O
condition	O
.	O

After	O
training	O
,	O
each	O
participant	O
was	O
assessed	O
via	O
a	B-O
Megacode	I-O
performance	I-O
examination	I-O
and	O
a	B-O
written	I-O
posttest	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Supplementation	O
with	O
a	B-I
blend	I-I
of	I-I
krill	I-I
and	I-I
salmon	I-I
oil	I-I
is	O
associated	O
with	O
increased	O
metabolic	O
risk	O
in	O
overweight	B-P
men	I-P
.	O

METHODS	O
:	O
The	O
design	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
crossover	O
trial	O
.	O

A	B-P
total	I-P
of	I-P
47	I-P
men	I-P
with	I-P
a	I-P
mean	I-P
	I-P
SD	I-P
age	I-P
of	I-P
46	I-P
.	I-P
5	I-P
	I-P
5	I-P
.	I-P
1	I-P
y	I-P
,	I-P
who	I-P
were	I-P
overweight	I-P
[	I-P
body	I-P
mass	I-P
index	I-P
(	I-P
in	I-P
kg	I-P
/	I-P
m	I-P
(	I-P
2	I-P
)	I-P
)	I-P
from	I-P
25	I-P
to	I-P
30	I-P
]	I-P
but	I-P
otherwise	I-P
healthy	I-P
,	O
received	O
5	B-I
1	I-I
-	I-I
g	I-I
capsules	I-I
of	I-I
KS	I-I
oil	I-I
or	O
a	O
control	O
(	O
canola	B-C
oil	I-C
)	O
for	O
8	O
wk	O
and	O
crossed	O
over	O
to	O
another	O
treatment	O
after	O
an	O
8	O
-	O
wk	O
washout	O
period	O
.	O

The	O
primary	O
outcome	O
was	O
insulin	B-O
sensitivity	I-O
assessed	O
by	O
using	O
the	B-O
Matsuda	I-O
method	I-O
from	I-O
an	I-O
oral	I-O
-	I-O
glucose	I-O
-	I-O
tolerance	I-O
test	I-O
.	O

Secondary	O
outcomes	O
included	O
lipid	B-O
profiles	I-O
,	O
inflammatory	B-O
markers	I-O
,	O
24	B-O
-	I-O
h	I-O
ambulatory	I-O
blood	I-O
pressure	I-O
,	O
and	O
carotid	B-O
artery	I-O
intimamedia	I-O
thickness	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
2	B-I
doses	I-I
of	I-I
vortioxetine	I-I
in	O
adults	B-P
with	I-P
major	I-P
depressive	I-P
disorder	I-P
.	O

METHODS	O
:	O
Adults	B-P
aged	I-P
18	I-P
-	I-P
75	I-P
years	I-P
with	I-P
MDD	I-P
(	I-P
DSM	I-P
-	I-P
IV	I-P
-	I-P
TR	I-P
)	I-P
and	I-P
Montgomery	I-P
-	I-P
Asberg	I-P
Depression	I-P
Rating	I-P
Scale	I-P
(	I-P
MADRS	I-P
)	I-P
total	I-P
score	I-P
?	I-P
26	I-P
were	I-P
randomized	O
(	O
1:1:1	O
)	O
to	O
receive	O
vortioxetine	B-I
10	O
mg	O
or	O
15	O
mg	O
or	O
placebo	B-C
once	O
daily	O
,	O
with	O
the	O
primary	O
efficacy	O
end	O
point	O
being	O
change	O
from	O
baseline	O
at	O
week	O
8	O
in	O
MADRS	O
analyzed	O
by	O
mixed	O
model	O
for	O
repeated	O
measures	O
.	O

Adverse	B-O
events	I-O
were	O
recorded	O
during	O
the	O
study	O
,	O
suicidal	B-O
ideation	I-O
and	O
behavior	B-O
were	O
assessed	O
using	O
the	B-O
Columbia	I-O
-	I-O
Suicide	I-O
Severity	I-O
Rating	I-O
Scale	I-O
(	I-O
C	I-O
-	I-O
SSRS	I-O
)	I-O
,	O
and	O
sexual	B-O
dysfunction	I-O
was	O
assessed	O
using	O
the	B-O
Arizona	I-O
Sexual	I-O
Experience	I-O
(	I-O
ASEX	I-O
)	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Placebo	O
-	O
controlled	O
clinical	O
trial	O
evaluating	O
9	B-I
.	I-I
5	I-I
%	I-I
hydrogen	I-I
peroxide	I-I
high	I-I
-	I-I
adhesion	I-I
whitening	I-I
strips	I-I
.	O

METHODS	O
:	O
In	O
this	O
parallel	O
-	O
design	O
,	O
double	O
-	O
blind	O
clinical	O
trial	O
,	O
54	B-P
adult	I-P
volunteers	I-P
were	O
randomized	O
to	O
an	B-I
experimental	I-I
9	I-I
.	I-I
5	I-I
%	I-I
hydrogen	I-I
peroxide	I-I
whitening	I-I
strip	I-I
or	O
placebo	B-C
strip	I-C
balancing	O
for	O
age	O
and	O
baseline	O
tooth	O
color	O
,	O
and	O
received	O
treatment	O
.	O

Strips	B-I
were	O
worn	O
on	O
the	O
maxillary	O
arch	O
30	O
minutes	O
daily	O
for	O
20	O
days	O
.	O

Efficacy	B-O
was	O
measured	O
objectively	O
as	O
L	B-O
*	I-O
a	I-O
*	I-O
b	I-O
*	I-O
color	I-O
change	O
from	O
digital	B-O
images	I-O
at	O
Days	O
4	O
,	O
7	O
,	O
15	O
,	O
and	O
21	O
.	O

-DOCSTART-	O

Title	O
:	O
Gluten	B-I
and	O
casein	B-I
supplementation	I-I
does	O
not	O
increase	O
symptoms	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	O

METHODS	O
:	O
A	O
randomised	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
was	O
performed	O
on	O
74	B-P
children	I-P
with	I-P
ASD	I-P
with	I-P
severe	I-P
maladaptive	I-P
behaviour	I-P
and	I-P
increased	I-P
urinary	I-P
I	I-P
-	I-P
FABP	I-P
.	O

Subjects	O
were	O
randomised	O
to	O
receive	O
gluten	B-I
-	I-I
casein	I-I
or	O
a	B-C
placebo	I-C
for	O
seven	O
days	O
.	O

We	O
evaluated	O
maladaptive	B-O
behaviour	I-O
before	O
and	O
after	O
supplementation	O
,	O
using	O
I	B-O
-	I-O
FABP	I-O
excretion	I-O
,	O
the	B-O
approach	I-O
withdrawal	I-O
problem	I-O
composite	O
subtest	O
of	O
the	B-O
Pervasive	I-O
Developmental	I-O
Disorder	I-O
Behavior	I-O
Inventory	I-O
and	O
the	B-O
Gastrointestinal	I-O
Symptom	I-O
Severity	I-O
Index	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
controlled	O
trial	O
of	O
the	B-I
SibworkS	I-I
group	I-I
program	I-I
for	O
siblings	B-P
of	I-P
children	I-P
with	I-P
special	I-P
needs	I-P
.	O

METHODS	O
:	O
SibworkS	B-I
is	O
a	O
six	O
-	O
week	O
manual	O
-	O
based	O
,	O
cognitive	B-I
-	I-I
behavioral	I-I
group	I-I
support	I-I
program	I-I
focussed	O
on	O
strengthening	B-O
siblings	I-O
'	I-O
perceived	I-O
social	I-O
support	I-O
,	O
self	B-O
-	I-O
esteem	I-O
,	O
problem	B-O
-	I-O
solving	I-O
skills	I-O
,	O
adaptive	B-O
coping	I-O
behaviors	I-O
and	O
positive	B-O
sibling	I-O
relationships	I-O
.	O

Fifty	B-P
-	I-P
six	I-P
children	I-P
aged	I-P
7	I-P
-	I-P
12	I-P
were	O
allocated	O
to	O
either	O
the	B-I
SibworkS	I-I
program	I-I
(	O
n=30	O
)	O
or	O
waitlist	B-C
control	O
(	O
n=26	O
)	O
in	O
alternating	O
sequence	O
.	O

The	O
primary	O
outcome	O
was	O
siblings	B-O
'	I-O
emotional	I-O
and	O
behavioral	B-O
functioning	I-O
.	O

Additional	O
outcomes	O
were	O
self	B-O
-	I-O
esteem	I-O
,	O
perceived	B-O
social	I-O
support	I-O
,	O
the	B-O
sibling	I-O
relationship	I-O
and	O
coping	B-O
behaviors	I-O
.	O

Siblings	B-P
were	O
followed	O
-	O
up	O
immediately	O
after	O
the	O
intervention	O
and	O
at	O
3	O
-	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Extended	B-I
-	I-I
Release	I-I
Guanfacine	I-I
for	O
Hyperactivity	O
in	O
Children	B-P
With	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
.	O

METHODS	O
:	O
In	O
a	O
multisite	O
,	O
randomized	O
clinical	O
trial	O
,	O
extended	B-I
-	I-I
release	I-I
guanfacine	I-I
was	O
compared	O
with	O
placebo	B-C
in	O
children	B-P
with	I-P
ASD	I-P
accompanied	O
by	O
hyperactivity	B-O
,	O
impulsiveness	B-O
,	O
and	O
distractibility	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
the	O
learning	O
conversation	O
improves	O
instructor	O
confidence	O
in	O
life	O
support	O
training	O
:	O
An	O
open	O
randomised	O
controlled	O
cross	O
-	O
over	O
trial	O
comparing	O
teaching	O
feedback	O
mechanisms	O
.	O

METHODS	O
:	O
Open	O
randomised	O
crossover	O
study	O
undertaken	O
between	O
October	O
2014	O
and	O
March	O
2015	O
at	O
the	O
University	O
of	O
Birmingham	O
,	O
United	O
Kingdom	O
.	O

Six	B-P
-	I-P
hundred	I-P
and	I-P
forty	I-P
healthcare	I-P
students	I-P
undertaking	I-P
a	I-P
European	I-P
Resuscitation	I-P
Council	I-P
(	I-P
ERC	I-P
)	I-P
BLS	I-P
course	I-P
were	O
enrolled	O
,	O
each	O
of	O
whom	O
was	O
randomised	O
to	O
receive	O
teaching	O
using	O
either	O
the	B-I
sandwich	I-I
technique	I-I
or	O
the	B-I
learning	I-I
conversation	I-I
.	O

Fifty	O
-	O
eight	O
instructors	O
were	O
randomised	O
to	O
initially	O
teach	O
using	O
either	O
the	B-I
learning	I-I
conversation	I-I
or	O
sandwich	B-I
technique	I-I
,	O
prior	O
to	O
crossing	O
-	O
over	O
and	O
teaching	O
with	O
the	O
alternative	O
technique	O
after	O
a	O
pre	O
-	O
defined	O
time	O
period	O
.	O

Outcome	O
measures	O
included	O
skill	O
acquisition	O
as	O
measured	O
by	O
an	B-O
end	I-O
-	I-O
of	I-O
-	I-O
course	I-O
competency	I-O
assessment	I-O
,	O
instructors	B-O
'	I-O
perception	I-O
of	I-O
teaching	I-O
with	I-O
each	I-O
feedback	I-O
technique	I-O
and	O
candidates	B-O
'	I-O
perception	I-O
of	I-O
the	I-O
feedback	I-O
they	O
were	O
provided	O
with	O
.	O

-DOCSTART-	O

Title	O
:	O
An	B-I
endovascular	I-I
simulation	I-I
exercise	I-I
among	O
radiology	B-P
residents	I-P
:	O
comparison	O
of	O
simulation	O
performance	O
with	O
and	O
without	O
practice	O
.	O

METHODS	O
:	O
Radiology	B-P
residents	I-P
were	O
guided	O
through	O
a	B-I
practice	I-I
simulation	I-I
and	O
lectured	B-I
on	I-I
endovascular	I-I
therapy	I-I
,	O
then	O
randomized	O
to	O
simulate	B-I
femoral	I-I
arterial	I-I
intervention	O
with	B-I
or	O
without	B-I
prior	I-I
iliac	I-I
simulation	I-I
.	O

Simulator	B-O
measurements	I-O
,	O
performance	B-O
grading	I-O
and	O
resident	B-O
surveys	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effectiveness	O
of	O
single	B-I
-	I-I
dose	I-I
metronidazole	I-I
therapy	I-I
for	O
patients	B-P
and	I-P
their	I-P
partners	I-P
with	I-P
bacterial	I-P
vaginosis	I-P
.	O

METHODS	O
:	O
In	O
addition	O
,	O
the	O
effectiveness	O
of	O
a	B-I
2	I-I
-	I-I
g	I-I
single	I-I
dose	I-I
of	I-I
metronidazole	I-I
was	O
compared	O
with	O
a	B-I
seven	I-I
-	I-I
day	I-I
course	I-I
of	I-I
500	I-I
mg	I-I
of	I-I
metronidazole	I-I
twice	O
a	O
day	O
in	O
patients	B-P
with	I-P
bacterial	I-P
vaginosis	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
trial	O
of	O
recombinant	B-I
alpha	I-I
2b	I-I
-	I-I
interferon	I-I
with	I-I
or	O
without	B-I
indomethacin	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
malignant	I-P
melanoma	I-P
.	O

METHODS	O
:	O
53	B-P
patients	I-P
were	O
stratified	O
according	O
to	O
performance	O
status	O
and	O
randomized	O
to	O
receive	O
alpha	B-I
2b	I-I
-	I-I
interferon	I-I
,	O
20	O
million	O
units	O
per	O
m2	O
i	O
.	O
v	O
.	O
,	O
5	O
days	O
per	O
week	O
for	O
4	O
weeks	O
followed	O
by	O
10	O
million	O
units	O
per	O
m2	O
s	O
.	O
c	O
.	O
three	O
times	O
per	O
week	O
,	O
either	O
with	B-I
or	O
without	B-I
indomethacin	I-I
,	O
25	O
mg	O
orally	O
three	O
times	O
a	O
day	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
propofol	B-I
and	O
isoflurane	B-I
on	O
haemodynamics	O
and	O
the	O
inflammatory	O
response	O
in	O
cardiopulmonary	O
bypass	O
surgery	O
.	O

METHODS	O
:	O
CRP	B-O
,	O
IL	B-O
-	I-O
6	I-O
,	O
IL	B-O
-	I-O
8	I-O
,	O
HIF	B-O
-	I-O
1?	I-O
(	O
ELISA	B-O
)	O
,	O
CD11	B-O
and	O
CD18	B-O
expression	I-O
(	O
flow	B-O
cytometry	I-O
)	O
,	O
and	O
haemoxygenase	B-O
(	O
HO	B-O
-	I-O
1	I-O
)	O
promoter	B-O
polymorphisms	I-O
(	O
PCR	B-O
/	O
electrophoresis	B-O
)	O
were	O
measured	O
before	O
anaesthetic	O
induction	O
,	O
4	O
hours	O
post	O
-	O
CPB	O
,	O
and	O
24	O
hours	O
later	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
therapeutic	B-I
horse	I-I
riding	I-I
on	O
gait	O
cycle	O
parameters	O
and	O
some	O
aspects	O
of	O
behavior	O
of	O
children	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
pupils	I-P
(	I-P
12	I-P
boys	I-P
and	I-P
14	I-P
girls	I-P
)	I-P
of	I-P
a	I-P
special	I-P
needs	I-P
school	I-P
participated	O
in	O
therapeutic	B-I
riding	I-I
.	O

We	O
analyzed	O
walking	B-O
twice	O
during	O
a	O
school	O
-	O
term	O
:	O
full	O
body	O
analyses	O
each	O
time	O
before	O
and	O
after	O
one	O
-	O
month	O
therapy	O
.	O

The	O
research	O
included	O
a	B-C
non	I-C
-	I-C
riding	I-C
control	O
group	O
.	O

All	O
together	O
104	O
analyses	O
were	O
performed	O
.	O

We	O
measured	O
mental	B-O
skills	I-O
using	O
Pedagogical	B-O
Analysis	I-O
and	I-O
Curriculum	I-O
(	I-O
PAC	I-O
)	I-O
test	I-O
consisting	O
of	O
four	O
parts	O
being	O
communication	B-O
,	O
self	B-O
care	I-O
,	O
motor	B-O
skills	I-O
and	O
socialization	B-O
.	O

The	B-O
Gait	I-O
Cycle	I-O
Analysis	O
consists	O
of	O
the	O
time	O
-	O
series	O
analysis	O
,	O
the	O
analysis	O
of	O
part	O
of	O
the	B-O
gait	I-O
cycle	I-O
and	O
the	B-O
measurement	I-O
of	I-O
joint	I-O
angles	I-O
in	O
each	O
plane	O
.	O

-DOCSTART-	O

Title	O
:	O
Amiprilose	B-I
hydrochloride	I-I
for	O
rheumatoid	O
arthritis	O
.	O

METHODS	O
:	O
Prospective	O
,	O
multicenter	O
,	O
randomized	O
,	O
parallel	O
group	O
,	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
12	O
-	O
week	O
trial	O
.	O

Two	B-P
hundred	I-P
and	I-P
one	I-P
functional	I-P
class	I-P
I	I-P
and	I-P
II	I-P
patients	I-P
with	I-P
definite	I-P
or	I-P
classic	I-P
rheumatoid	I-P
arthritis	I-P
,	I-P
previously	I-P
untreated	I-P
with	I-P
disease	I-P
modifying	I-P
antirheumatic	I-P
drugs	I-P
.	O

Patients	O
were	O
withdrawn	O
from	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
therapy	O
.	O

Those	O
who	O
flared	O
were	O
randomly	O
assigned	O
to	O
amiprilose	B-I
HCl	I-I
,	O
6	O
g	O
/	O
d	O
,	O
or	O
placebo	B-C
for	O
12	O
weeks	O
.	O

No	O
concomitant	O
anti	O
-	O
inflammatory	O
or	O
antirheumatic	O
drug	O
therapy	O
was	O
permitted	O
during	O
the	O
study	O
.	O

Combination	O
acetaminophen	O
and	O
propoxyphene	O
napsylate	O
was	O
the	O
only	O
supplemental	O
analgesic	O
medication	O
allowed	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Low	B-I
-	I-I
Dose	I-I
Buspirone	I-I
for	O
Restricted	O
and	O
Repetitive	O
Behavior	O
in	O
Young	B-P
Children	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
:	O
A	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
Children	B-P
2	I-P
-	I-P
6	I-P
years	I-P
of	I-P
age	I-P
with	I-P
ASD	I-P
(	I-P
N	I-P
=	I-P
166	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
placebo	B-C
or	O
2	B-I
.	I-I
5	I-I
or	O
5	O
.	B-I
0	I-I
mg	I-I
of	I-I
buspirone	I-I
twice	O
daily	O
.	O

The	O
primary	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
24	O
weeks	O
of	O
buspirone	B-I
on	O
the	B-O
Autism	I-O
Diagnostic	I-O
Observation	I-O
Schedule	I-O
(	I-O
ADOS	I-O
)	I-O
Composite	I-O
Total	I-O
Score	I-O
.	O

Secondary	O
objectives	O
included	O
evaluating	O
the	B-O
effects	I-O
of	I-O
buspirone	I-O
on	I-O
social	I-O
competence	I-O
,	O
repetitive	B-O
behaviors	I-O
,	O
language	B-O
,	O
sensory	B-O
dysfunction	I-O
,	O
and	O
anxiety	B-O
and	O
to	O
assess	O
side	B-O
effects	I-O
.	O

Positron	B-O
emission	I-O
tomography	I-O
measures	O
of	O
tryptophan	B-O
metabolism	I-O
and	O
blood	B-O
serotonin	I-O
concentrations	I-O
were	O
assessed	O
as	O
predictors	B-O
of	I-O
buspirone	I-O
efficacy	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Dacarbazine	B-I
versus	O
dacarbazine	B-I
-	O
vindesine	B-I
in	O
disseminated	O
malignant	O
melanoma	O
:	O
a	O
randomized	O
phase	O
II	O
study	O
.	O

METHODS	O
:	O
Dacarbazine	B-I
was	O
given	O
i	O
.	O
v	O
.	O
at	O
250	O
mg	O
m	O
-	O
2	O
per	O
day	O
X	O
V	O
every	O
4	O
weeks	O
.	O

In	O
the	O
combination	O
regimen	O
vindesine	B-I
given	O
at	O
3	O
mg	O
m	O
-	O
2	O
per	O
week	O
was	O
included	O
.	O

-DOCSTART-	O

Title	O
:	O
Methods	O
for	O
assessing	O
treatment	O
efficacy	O
in	O
trials	O
for	O
adjuvant	O
therapy	O
for	O
breast	O
cancer	O
.	O

-DOCSTART-	O

Title	O
:	O
Protective	O
effect	O
of	O
high	B-I
-	I-I
dose	I-I
medroxyprogesterone	I-I
acetate	I-I
(	I-I
HD	I-I
-	I-I
MPA	I-I
)	I-I
on	O
hematological	O
toxicity	O
induced	O
by	O
chemotherapy	O
for	O
advanced	O
solid	O
tumors	O
:	O
a	O
multicentric	O
controlled	O
clinical	O
trial	O
.	O

MPA	O
-	O
Hematology	O
Italian	O
Cooperative	O
Group	O
.	O

METHODS	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
conducted	O
comparing	O
active	O
treatment	O
with	O
placebo	B-C
in	O
227	B-P
patients	I-P
with	I-P
breast	I-P
,	I-P
colorectal	I-P
,	I-P
lung	I-P
and	I-P
other	I-P
solid	I-P
forms	I-P
of	I-P
cancer	I-P
.	O

Combination	B-I
therapy	I-I
,	I-I
(	I-I
CT	I-I
)	I-I
conventionally	O
employed	O
for	O
the	O
various	O
types	O
of	O
tumor	O
involved	O
,	O
was	O
associated	O
with	O
MPA	B-I
(	O
117	O
patients	O
)	O
or	O
placebo	B-C
(	O
110	O
patients	O
)	O
.	O

MPA	B-I
was	O
given	O
orally	O
as	O
tablets	O
,	O
as	O
a	O
dose	O
of	O
500	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
elimination	I-I
of	O
group	O
-	O
B	O
streptococci	O
in	O
urine	O
in	O
prevention	O
of	O
preterm	O
labour	O
.	O

METHODS	O
:	O
Urine	B-O
samples	I-O
from	O
4122	B-P
women	I-P
at	I-P
27	I-P
-	I-P
31	I-P
weeks	I-P
'	I-P
gestation	I-P
were	O
examined	O
for	O
bacteria	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
,	O
controlled	O
study	O
these	O
patients	O
were	O
given	O
either	O
penicillin	B-I
(	O
10	O
(	O
6	O
)	O
IU	O
three	O
times	O
daily	O
for	O
6	O
days	O
;	O
37	O
patients	O
)	O
or	O
placebo	B-C
(	O
32	O
patients	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Bronchial	O
carcinoma	O
.	O

II	O
.	O

Quantitative	O
measurements	O
of	O
the	O
quality	O
of	O
survival	O
.	O

A	O
prospective	O
randomized	O
study	O
of	O
the	O
result	O
of	O
therapy	O
in	O
inoperable	B-P
patients	I-P
with	I-P
advanced	I-P
disease	I-P
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
eight	I-P
bronchial	I-P
carcinoma	I-P
patients	I-P
in	I-P
clinicoanatomical	I-P
stage	I-P
4	I-P
of	I-P
the	I-P
disease	I-P
(	I-P
advanced	I-P
disease	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
groups	O
for	O
radiotherapy	B-I
,	O
chemotherapy	B-I
(	I-I
cyclophosphamide	I-I
)	I-I
and	O
placebo	B-C
treatment	I-C
,	O
respectively	O
.	O

The	O
results	O
were	O
assessed	O
by	O
the	B-O
survival	I-O
time	I-O
and	O
quality	B-O
of	I-O
survival	I-O
.	O

-DOCSTART-	O

Title	O
:	O
5	B-I
-	I-I
Fluorouracil	I-I
,	I-I
adriamycin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FAC	I-I
)	I-I
vs	O
.	O
5	B-I
-	I-I
fluorouracil	I-I
,	I-I
epirubicin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FEC	I-I
)	I-I
in	O
metastatic	O
breast	O
cancer	O
.	O

-DOCSTART-	O

Title	O
:	O
Flow	O
-	O
cytometric	O
studies	O
with	O
eleutherococcus	B-I
senticosus	I-I
extract	I-I
as	O
an	B-I
immunomodulatory	I-I
agent	I-I
.	O

METHODS	O
:	O
Volunteers	O
in	O
the	O
verum	O
group	O
received	O
10	B-I
ml	I-I
of	I-I
an	I-I
ethanolic	I-I
(	I-I
vincamine	I-I
free	I-I
)	I-I
eleutherococcus	I-I
senticosus	I-I
preparation	I-I
,	O
3	O
times	O
daily	O
for	O
4	O
weeks	O
.	O

In	O
the	B-C
placebo	I-C
,	O
the	B-I
eleutherococcus	I-I
extract	I-I
was	O
substituted	O
by	O
additional	B-C
wine	I-C
,	O
resulting	O
in	O
identical	O
final	O
concentrations	O
of	O
ethanol	O
in	O
both	O
preparations	O
.	O

The	O
purpose	O
of	O
the	O
double	O
-	O
blind	O
study	O
was	O
the	O
demonstration	O
of	O
possible	O
effects	O
on	O
the	B-O
cellular	I-O
immune	I-O
status	I-O
,	O
as	O
determined	O
by	O
quantitative	B-O
flow	I-O
cytometry	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Antihypertensive	O
effect	O
of	O
single	B-I
doses	I-I
of	I-I
enalapril	I-I
in	O
hypertensive	B-P
patients	I-P
treated	I-P
with	I-P
bendrofluazide	I-P
.	O

METHODS	O
:	O
Enalapril	B-I
in	O
single	O
doses	O
of	O
10	O
and	O
20	O
mg	O
was	O
given	O
to	O
13	B-P
hypertensive	I-P
patients	I-P
on	I-P
treatment	I-P
with	I-P
bendrofluazide	I-P
5	I-P
mg	I-P
daily	I-P
in	I-P
a	I-P
randomised	I-P
,	I-P
crossover	I-P
,	I-P
placebo	I-P
controlled	I-P
study	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
effects	O
of	O
pinacidil	B-I
and	O
nifedipine	B-I
in	O
the	O
treatment	O
of	O
arterial	O
hypertension	O
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
dependent	O
response	O
of	O
symptoms	O
,	O
pituitary	O
,	O
and	O
bone	O
to	O
transdermal	B-I
oestrogen	I-I
in	O
postmenopausal	B-P
women	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
prophylaxis	I-I
in	O
high	O
-	O
risk	O
head	O
and	O
neck	O
surgery	O
:	O
one	O
-	O
day	O
vs	O
.	O
five	O
-	O
day	O
therapy	O
.	O

METHODS	O
:	O
A	O
multi	O
-	O
institutional	O
prospective	O
randomized	O
double	O
-	O
blind	O
study	O
was	O
designed	O
.	O

Patients	O
who	O
were	O
identified	O
as	O
requiring	O
pedicled	O
flap	O
reconstruction	O
were	O
potential	O
candidates	O
for	O
the	O
study	O
.	O

Later	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
cefoperazone	B-I
sodium	I-I
for	O
either	O
24	O
hours	O
or	O
120	O
hours	O
.	O

In	O
each	O
case	O
,	O
the	O
drug	O
was	O
administered	O
intravenously	O
,	O
beginning	O
1	O
to	O
2	O
hours	O
preoperatively	O
and	O
continued	O
for	O
the	O
prescribed	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Total	O
parenteral	O
nutrition	O
in	O
colon	O
surgery	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Psoriasis	O
of	O
the	O
scalp	O
treated	O
with	O
Grenz	B-I
rays	I-I
or	O
topical	B-I
corticosteroid	I-I
combined	O
with	O
Grenz	B-I
rays	I-I
.	O

A	O
comparative	O
randomized	O
trial	O
.	O

METHODS	O
:	O
One	O
group	O
received	O
4	B-I
Gy	I-I
of	I-I
Grenz	I-I
rays	I-I
administered	O
on	O
six	O
occasions	O
at	O
intervals	O
of	O
1	O
week	O
and	O
the	O
other	O
group	O
was	O
given	O
the	B-I
same	I-I
Grenz	I-I
ray	I-I
treatment	I-I
plus	O
topical	B-I
corticosteroid	I-I
.	O

The	O
patients	O
were	O
assessed	O
before	O
and	O
after	O
Grenz	O
ray	O
therapy	O
and	O
were	O
followed	O
-	O
up	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Educational	B-I
intervention	I-I
for	O
altering	O
water	O
-	O
sanitation	O
behavior	O
to	O
reduce	O
childhood	O
diarrhea	O
in	O
urban	O
Bangladesh	O
:	O
impact	O
on	O
nutritional	O
status	O
.	O

METHODS	O
:	O
Fifty	B-P
-	I-P
one	I-P
communities	I-P
of	I-P
38	I-P
families	I-P
each	I-P
were	O
randomized	O
to	O
receive	O
the	O
intervention	O
or	O
no	O
intervention	O
.	O

